Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.59 |
| ▸ | CA2 | P00918 | 6/20 | 0.59 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.59 |
| ▸ | PARP1 | P09874 | 1/20 | 0.59 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.59 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.59 |
| ▸ | CES2 | O00748 | 2/20 | 0.57 |
| ▸ | CES1 | P23141 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | PLK1 | P53350 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11212295 | 0.83 | CES2 (0.61) | CA1CA2PARP10PARP1PARP2 | |
| SCHEMBL1659309 | 0.83 | HPGD (0.73) | CA1CA2PARP10PARP1PARP2 | |
| SCHEMBL2579853 | 0.82 | CA1 (0.57) | CA1CA2PARP10PARP1PARP2 | |
| SCHEMBL30527863 | 0.81 | CES2 (0.64) | CA1CA2PARP10PARP1PARP2 | |
| SCHEMBL286256 | 0.80 | CES2 (0.57) | CA1CA2PARP10PARP1PARP2 | |
| SCHEMBL7736889 | 0.79 | CES2 (0.52) | CA1CA2PARP10PARP1PARP2 | |
| SCHEMBL28183213 | 0.79 | CES2 (0.65) | CA1CA2PARP10PARP1PARP2 | |
| SCHEMBL5858910 | 0.79 | HPGD (0.62) | CA1CA2PARP10PARP1PARP2 | |
| SCHEMBL6806574 | 0.78 | HSD17B1 (0.65) | CA1CA2PARP10PARP1PARP2 | |
| SCHEMBL29194225 | 0.78 | CA1 (0.59) | CA1CA2PARP10PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2594555-B1 | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | ASKA PHARM CO LTD (JP) | 2018-03-07 | — | — | EP | disclosed |
| EP-2594555-B1 | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | ASKA PHARM CO LTD (JP) | 2018-03-07 | — | — | EP | disclosed |
| CN-105753858-A | Heterocyclic compound and p27Kip1 degradation inhibitor | ASKA制药株式会社 | 2016-07-13 | — | — | CN | disclosed |
| CN-102985405-B | Heterocyclic compounds and p27Kip1Decomposition inhibitor | ASKA制药株式会社 | 2016-07-06 | — | — | CN | disclosed |
| US-9200008-B2 | Heterocyclic compound and p27Kip1 degradation inhibitor | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-9200008-B2 | Heterocyclic compound and p27Kip1 degradation inhibitor | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-9200008-B2 | Heterocyclic compound and p27Kip1 degradation inhibitor | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| EP-2594555-A1 | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | ASKA Pharmaceutical Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| EP-2594555-A1 | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | ASKA Pharmaceutical Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-20130079306-A1 | HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-28 | — | — | US | disclosed |
| US-20130079306-A1 | HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-28 | — | — | US | disclosed |
| US-20130079306-A1 | HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-28 | — | — | US | disclosed |
| CN-102985405-A | Heterocyclic compounds and p27Kip1Decomposition inhibitor | ASKA PHARM CO LTD | 2013-03-20 | — | — | CN | disclosed |
| WO-2012002527-A1 | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | あすか製薬株式会社 (JP) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079306-A1 | HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR | CDKN1A, SKP2, CCNI | CA1 1503/4885CA2 790/4885PARP10 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.